Pharma fund to sell rare bonds backed by drug royalties
A private equity firm with investments in over 40 royalty streams from drug and life science companies is about to enter the capital markets with a type of deal not seen in the US in two years.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: